Back to Search
Start Over
Bortezomib and Arsenic Trioxide Activity on a Myelodysplastic Cell Line (P39): A Gene Expression Study
- Source :
- Turkish Journal of Hematology, Vol 32, Iss 3, Pp 206-212 (2015)
- Publication Year :
- 2015
- Publisher :
- Galenos Publishing House, 2015.
-
Abstract
- Objective: We aimed to understand the molecular pathways affected by bortezomib and arsenic trioxide treatment on myelomonocytoid cell line P39. Materials and Methods: Oligonucleotide microarray platforms were used for gene expression and pathway analysis. Confirmation studies were performed using quantitative real time PCR. Results: Bortezomib treatment has shown upregulated DIABLO and NF-κBIB (a NF-κB inhibitor) and downregulated NF-κB1, NF-κB2, and BIRC1 gene expressions. Combination treatment of the two compounds showed gene expression deregulations in concordance by the results of single bortezomib treatment. Especially, P53 was a pathway more significantly modified and a gene network centralized around the beta estradiol gene. Beta estradiol, BRCA2, and FOXA1 genes were remarkable deregulations in our findings. Conclusion: Results support the suggestions about possible use of proteasome inhibitors in the treatment of high-risk myelodysplastic syndrome (MDS). NF-κB was observed as an important modulator in leukemic transformation of MDS.
Details
- Language :
- English
- ISSN :
- 13007777 and 13085263
- Volume :
- 32
- Issue :
- 3
- Database :
- Directory of Open Access Journals
- Journal :
- Turkish Journal of Hematology
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.886f63060f644c19bb2719161c4653d8
- Document Type :
- article
- Full Text :
- https://doi.org/10.4274/tjh.2014.0058